Immune Checkpoint Inhibitors for Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review

Second-line treatment options are limited for patients with advanced non-small cell lung cancer (NSCLC). Standard therapy includes cytotoxic agents, docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiological response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kYcnQv
via IFTTT